Cognitive deficits in Parkinson&amp;rsquo;s disease: current perspectives

Cosgrove, Jeremy; Alty, Jane

doi:10.2147/jprls.s125064

Cited by 4 publications

(4 citation statements)

References 112 publications

(154 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, studies until now have shown that there is an only modest benefit for antidementia drugs that are licensed for PDD. These findings together suggest that there is an emerging need for a mechanism-based clinical treatment strategy for cognitive impairment in PD 103…”

Section: Possible Procognitive Effects Of Minocycline In Clinical Trimentioning

confidence: 91%

The therapeutic role of minocycline in Parkinson’s disease

Çankaya¹,

Çankaya²,

Kılıç³

et al. 2019

DIC

View full text Add to dashboard Cite

Minocycline, a semisynthetic tetracycline-derived antibiotic, has been shown to exert anti-apoptotic, anti-inflammatory, and antioxidant effects. Furthermore, there is rapidly growing evidence suggesting that minocycline may have some neuroprotective activity in various experimental models such as cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, Parkinson’s disease (PD), Huntington’s disease, and multiple sclerosis. In this perspective review, we summarize the preclinical and clinical findings suggesting the neuroprotective role of minocycline in PD.

show abstract

Section: Possible Procognitive Effects Of Minocycline In Clinical Trimentioning

confidence: 91%

The therapeutic role of minocycline in Parkinson’s disease

Çankaya¹,

Çankaya²,

Kılıç³

et al. 2019

DIC

View full text Add to dashboard Cite

show abstract

“…Often, in end-of-life situations, the patient is unable to communicate because of fatigue, weakness, and a reduced level of awareness due to drugs to alleviate pain ( Herr et al, 2006 ). At the same time, the advanced stage of some pathologies is associated to cognitive impairment ( Liszewski et al, 2004 ; Cysique et al, 2006 ; Green, 2006 ; Pandharipande et al, 2013 ; Cosgrove and Alty, 2018 ). The severe physical and cognitive impairment of many patients hampers the assessment and treatment of their psychological needs ( Sampson et al, 2006 ; Davis et al, 2016 ), especially those related to their emotional well-being.…”

Section: Introductionmentioning

confidence: 99%

Emotional Distress of Patients at End-of-Life and Their Caregivers: Interrelation and Predictors

et al. 2018

View full text Add to dashboard Cite

Background: Patients at the end of life and their families experience a strong emotional impact. The well-being of these patients and that of their family caregiver are related.Aim: To study the variables related with the emotional well-being of patients with and without cognitive impairment at the end of life and that of their primary family caregivers.Design: Cross- sectional study.Participants: Data was collected from 202 patients at the end of life with different diagnosis (COPD, cancer, and frail elderly) as well as from their respective 202 primary family caregivers.Results: Structural equation models indicated that the emotional state of the patients was best predicted by their functional independence and the burden of their family caregivers. In addition, the emotional state of the primary family caregiver was predicted by their burden and not by the cognitive state or the functional independence of the patient. Nevertheless, the burden of the family caregiver, which is the only variable predicting both the emotional state of the patient and that of the caregiver, was directly related with the functional independence of the patient and indirectly with the patient’s cognitive state.Conclusion: The family caregiver’s burden is an important factor to take into consideration when aiming to reduce the emotional distress of patients at the end of life with different diagnosis -whether or not they present significant cognitive impairment- and that of their family caregivers.

show abstract

“…[1] Modern perception has changed the perception of PD from a pure movement (or motor) disorder to a multifactorial disease. [20] Cognitive impairment in PD is characterized by predominant executive deficits, visuospatial dysfunction, and relatively affected memory. [21] Natural products have definitive molecular or pharmacological effects that are prone to contribute to the development of neuroprotective agents against PD.…”

Section: Discussionmentioning

confidence: 99%

Untitled

2023

IJGP

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) caused due to neuroinflammation and oxidative stress associated with motor and non-motor complications. Neuroprotection strategies create a hope for patients. Natural products have been increasing the gain to have specific molecular or pharmacological activities that are likely to supply the development of neuroprotective agents against PD. Cissus quadrangularis constitutes all suitable physical and chemical properties and its ability to cross the blood-brain barrier making it a relevant candidate for the treatment of neuroprotection in PD. Materials and Methods: The stem part of the plant was extracted with distilled water and ethanol. The antiparkinson's activity of both extracts of C. quadrangularis was evaluated using rotenoneinduced excitotoxicity model in zebrafish for 96 h resulting in alterations in swimming pattern measured through a video recording system. Further, cognitive improvement activity in PD of both extracts of plant was evaluated using reserpine-induced cognitive impairments in mice for 29 days. Biochemical parameters, that is, levels of catalase and glutathione (GSH) were analyzed using UV-visible spectrophotometer. Results: The aqueous extract of C. quadrangularis (AECQ) showed a significant and dose-dependent effect against rotenone-induced PD in adult zebrafish's at a dose of 4 and 10 µg/mL and cognitive improvement activity against reserpine-induced cognitive impairment in mice at a dose of 200 mg/kg and 500 mg/kg. The AECQ also showed a significant in vivo antioxidant potential by restoring the levels of catalase and GSH. The results of the present study demonstrate the potential antiparkinson's properties of the aqueous extract. Conclusion: The result of the present study conclusively shows the Anti-Parkinson's activity of C. quadrangularis and improved cognition in PD.

show abstract

Cognitive deficits in Parkinson’s disease: current perspectives

Cited by 4 publications

References 112 publications

The therapeutic role of minocycline in Parkinson’s disease

The therapeutic role of minocycline in Parkinson’s disease

Emotional Distress of Patients at End-of-Life and Their Caregivers: Interrelation and Predictors

Untitled

Contact Info

Product

Resources

About